XML 110 R98.htm IDEA: XBRL DOCUMENT
v3.26.1

Revenue from contracts with customers - Disclosures about major customers and credit risk (Details) - EUR (€) € in Millions | 6 Months Ended
--- | ---
Jun. 30, 2026 | Jun. 30, 2025
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | € 22,106 | € 19,889
Dupixent |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 9,324 | 7,312
ALTUVIIIO |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 674 | 542
Fabrazyme |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 523 | 525
Nexviazyme/Nexviadyme |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 426 | 387
Cerezyme |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 352 | 363
Ayvakit |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 367 | 0
Sarclisa |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 354 | 276
Lantus |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 813 | 876
Toujeo |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 729 | 692
Plavix |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 440 | 473
Lovenox |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 364 | 447
Rezurock |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 296 | 263
Industrial sales |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 190 | 251
Polio/pertussis/Hib primary vaccines and boosters, incl. Heplisav-B |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 1,364 | 1,361
RSV vaccines (Beyfortus) |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 392 | 356
Meningitis, travel and endemics vaccines |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 565 | 609
COVID-19 and Influenza vaccines |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 121 | 214
Of which total launches |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 3,047 | 2,100
Europe |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 4,304 | 4,144
Europe | Dupixent |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 1,146 | 944
Europe | ALTUVIIIO |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 0 | 0
Europe | Fabrazyme |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 138 | 134
Europe | Nexviazyme/Nexviadyme |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 152 | 132
Europe | Cerezyme |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 126 | 119
Europe | Ayvakit |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 44 | 0
Europe | Sarclisa |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 108 | 83
Europe | Lantus |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 146 | 149
Europe | Toujeo |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 259 | 248
Europe | Plavix |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 40 | 44
Europe | Lovenox |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 202 | 247
Europe | Rezurock |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 36 | 23
Europe | Industrial sales |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 181 | 241
Europe | Polio/pertussis/Hib primary vaccines and boosters, incl. Heplisav-B |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 206 | 223
Europe | RSV vaccines (Beyfortus) |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 87 | 85
Europe | Meningitis, travel and endemics vaccines |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 118 | 96
Europe | COVID-19 and Influenza vaccines |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 33 | 52
Europe | Of which total launches |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 546 | 423
United States |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 11,633 | 9,535
United States | Dupixent |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 6,922 | 5,283
United States | ALTUVIIIO |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 576 | 456
United States | Fabrazyme |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 256 | 261
United States | Nexviazyme/Nexviadyme |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 211 | 195
United States | Cerezyme |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 86 | 91
United States | Ayvakit |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 322 | 0
United States | Sarclisa |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 132 | 119
United States | Lantus |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 344 | 395
United States | Toujeo |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 134 | 126
United States | Plavix |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 2 | 3
United States | Lovenox |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 5 | 9
United States | Rezurock |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 218 | 220
United States | Industrial sales |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 7 | 1
United States | Polio/pertussis/Hib primary vaccines and boosters, incl. Heplisav-B |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 487 | 320
United States | RSV vaccines (Beyfortus) |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 65 | 68
United States | Meningitis, travel and endemics vaccines |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 268 | 319
United States | COVID-19 and Influenza vaccines |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 16 | 54
United States | Of which total launches |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 1,891 | 1,204
Other countries |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 6,169 | 6,210
Other countries | Dupixent |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 1,256 | 1,085
Other countries | ALTUVIIIO |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 98 | 86
Other countries | Fabrazyme |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 129 | 130
Other countries | Nexviazyme/Nexviadyme |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 63 | 60
Other countries | Cerezyme |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 140 | 153
Other countries | Ayvakit |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 1 | 0
Other countries | Sarclisa |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 114 | 74
Other countries | Lantus |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 323 | 332
Other countries | Toujeo |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 336 | 318
Other countries | Plavix |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 398 | 426
Other countries | Lovenox |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 157 | 191
Other countries | Rezurock |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 42 | 20
Other countries | Industrial sales |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 2 | 9
Other countries | Polio/pertussis/Hib primary vaccines and boosters, incl. Heplisav-B |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 671 | 818
Other countries | RSV vaccines (Beyfortus) |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 240 | 203
Other countries | Meningitis, travel and endemics vaccines |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 179 | 194
Other countries | COVID-19 and Influenza vaccines |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | 72 | 108
Other countries | Of which total launches |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |
Net sales | € 610 | € 473

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Note Expiry date 2027-01-01 -Name IAS -Number 1 -IssueDate 2025-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_RevenueFromSaleOfGoods
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_DupixentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_AltuviiioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_FabrazymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_NexviazymeNexviadymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_CerezymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_AyvakitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_SarclisaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_LantusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_ToujeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_PlavixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_LovenoxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_RezurockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_IndustrialSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_PolioPertussisHibPrimaryVaccinesAndBoostersIncl.HeplisavBMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_RSVVaccinesBeyfortusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_MeningitisTravelAndEndemicsVaccinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_COVID19AndInfluenzaVaccinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_LaunchesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=sny_OtherCountriesInSegmentResultsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |